Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Fundamentally, we are stronger every quarter, which we believe would otherwise lead to broader interest from institutional investors that today simply cannot buy the shares since they are under their minimum price thresholds of $1 or $3 or even $5 a share |
| The ability to, in some way, to monitor pet vitals would be, I think, an advantage in a number of scenarios outside of the sort of classic vet practice and now that we've finalized the acquisition of SMP and acquired VetGuardian in total we're able to look into that and that's actually pretty encouraging |
| Overall, this was a remarkable quarter |
| We delivered record revenues, our highest ever quarterly revenue, beating last year's record fourth quarter, all while maintaining high margins and reducing operating cash burn |
| PulseVet product sales for the third quarter of 2023 were up 21% versus the third quarter of 2022, reflecting an acceleration in consumable growth in the high margin trode business |
| The VetGuardian platform improves the quality of care for pets in the ICU during recovery from surgery and for overnight stays in the clinic |
| Three, leverage our strong balance sheet and cash position to continue to invest in commercial and R&D activities as well as remaining opportunistically acquisitive |
| We had a very strong record-breaking third quarter |
| Much like equine eACTH, we're pleased with the early indicators and see future upside |
| As Larry noted earlier, our recent acquisition of Qorvo Biotechnologies LLC should improve margins and accelerate development |
| So, I mean, most of all, it's really driving for a cash flow positive and profitability |
| We believe PulseVet sales will remain strong through the end of 2023 |
| While Larry and I are very optimistic about achieving our strategic and operational objectives, we are likely to recommend a reverse stock split |
| Our operational performance remains excellent and we have a strong balance sheet |
| Our margins remain strong at 69%, offering 67% in the second quarter |
| Remembering that we have a strong liquidity position of $118 million in cash, cash equivalents and available for sale securities, we remain well-funded for the foreseeable future |
| Although we are starting to see many operating improvements, the overall improvement in this year's number included many one-time benefits such as the gain from the acquisition of the SMP and the related tax benefits and we also had higher interest income this year |
| One, as Larry noted in his prepared remarks, we continue to have rapid top-line growth both organically and through acquisition |
| We are also pleased to announce this was the best quarter ever for Assisi product sales |
| This is a growth driver for us going forward and an opportunity to expand product offerings within our already large equine customer base |
| I mean as we continue to post quarterly revenue growth, we continue to post significant revenue growth year-over-year, much, much higher than other animal health companies are as we continue to put forward margins |
| We are benefiting from strong demand from our retail channels, including our recently re-established relationship with Chewy |
| We're also pleased to report that we're continuing to see leverage developing on the G&A line as we continue our journey towards cash flow and GAAP profitability |
| Before I hand the call to Peter, I want to reiterate that we are very happy with what we achieved during the third quarter and look forward to building on this momentum as we continue to be very optimistic about an even stronger fourth quarter |
| We were able to grow revenue by 31% while maintaining near 70% gross margins |
| Two, we continue to have industry-leading margins, leveraging our recent integrations to improve those margins and accelerate our pathway to profitability |
| Primarily it was the ability to immediately realize improvements in margin and to do that with a very, very high probability of success from an execution standpoint |
| TRUFORMA nearly doubled revenues year-over-year driven by organic growth |
| While we're pleased with the early success of the expanded sales organization, we expect even more performance from the concerned team with new leadership and as they become more seasoned |
| We talked about that a little bit in the text of the initial comments, and we're very optimistic about those, as those are absolutely assays that are not currently available at the point-of-care that veterinarians would really like to have available at the point-of-care because you bring your dog in for diarrhea and vomiting, they'd like to know right then and there what's the issue so that they can start treatment right away |
| Statement |
|---|
| What we were concerned about and what we were addressing was the lack of liquidity from our retail, individual retail shareholders |
| The numbers were about $2 million below my expectation |
| The uncertainty around a potential delisting looming over us, not to mention an actual delisting itself that would put us in the over-the-counter markets, tend to put downward pressure on stocks |
| I'm a little disappointed in that |
| Keep in mind that many reverse stock splits are done under extreme duress because a business is underperforming and/or needs desperately to raise capital to remain solvent |
| It's a very tough market right now |
| But and I would also challenge the assumption |
| Can I understand what you're trying to say about the stock split? You know, and I wrote this down, you said the lack of liquidity goes away |
| But I think so there's a risk of that, a pretty good risk |
| So it was really, it was in fact a surprise to us that that it fell below $0.20 for more than 30 days I mean obviously we saw it coming during that period of time when it was below that |
| So this was not a good quarter |
| So the scales have changed before we balanced the potential risk of a reduction in market cap value following a reverse split against a delayed opportunity to attract institutional investors and indices and came down on the side of waiting until we were cash flow positive |
| If there is nothing inherent in a reverse split that automatically results in a loss of market cap |
| Larry Heaton So in the animal health industry as I'm sure you're you know super familiar with, the first and third quarters are generally lower than second and fourth just because of the cyclical nature of visits to pets |
| And let me just say one last thing is, I think, we're, it's a semantics issue |
| The plan for rising revenues look like it's delayed |
| The adjusted cash in this quarter of $2.9 million shows that we continue to decrease and was lower than our historical burn, which is usually around $3 million to $4 million per quarter |
| That compares to a net loss of $5.8 million or $0.005 per share last year |
| Net loss for the three months ended September 30th, 2023 was only $0.3 million or $0.001 per share |
| But now we have to add the risk of being delisted and moving to OTC markets to that limited potential of attracting institutional investors and indices |
Please consider a small donation if you think this website provides you with relevant information